Does the media favor AXSM or JAZZ?

In the previous week, Jazz Pharmaceuticals had 20 more articles in the media than Axsome Therapeutics. MarketBeat recorded 35 mentions for Jazz Pharmaceuticals and 15 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.59 beat Jazz Pharmaceuticals' score of 0.53 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Jazz Pharmaceuticals 10 Very Positive mention(s) 7 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ONC or AXSM?

In the previous week, BeOne Medicines had 17 more articles in the media than Axsome Therapeutics. MarketBeat recorded 32 mentions for BeOne Medicines and 15 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.59 beat BeOne Medicines' score of 0.48 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 9 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Axsome Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to RPRX or AXSM?

In the previous week, Royalty Pharma had 6 more articles in the media than Axsome Therapeutics. MarketBeat recorded 21 mentions for Royalty Pharma and 15 mentions for Axsome Therapeutics. Royalty Pharma's average media sentiment score of 0.96 beat Axsome Therapeutics' score of 0.59 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 8 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable earnings and valuation, AXSM or ZTS?

Zoetis has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Axsome Therapeutics $638.50M 17.15 -$183.17M -$3.73 N/A Zoetis $9.47B 3.21 $2.67B $6.07 11.95

Is AXSM or ZTS more profitable?

Zoetis has a net margin of 27.49% compared to Axsome Therapeutics' net margin of -26.59%. Zoetis' return on equity of 74.89% beat Axsome Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Axsome Therapeutics -26.59% -267.16% -28.53% Zoetis 27.49% 74.89% 18.59%

Does the media favor AXSM or ZTS?

In the previous week, Zoetis had 29 more articles in the media than Axsome Therapeutics. MarketBeat recorded 44 mentions for Zoetis and 15 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.59 beat Zoetis' score of 0.58 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Zoetis 16 Very Positive mention(s) 4 Positive mention(s) 13 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Positive

Live Earnings Conference Call: Axsome Therapeutics' Q2 2026 earnings call is happening now. Listen live.

Axsome Therapeutics (AXSM) Competitors

$212.74 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$215.57 +2.83 (+1.33%)

As of 08:02 AM Eastern

Compare

AXSM vs. JAZZ, TEVA, ONC, RPRX, and ZTS

Should you buy Axsome Therapeutics stock or one of its competitors? MarketBeat compares Axsome Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Axsome Therapeutics include Jazz Pharmaceuticals (JAZZ), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Royalty Pharma (RPRX), and Zoetis (ZTS). These companies are all part of the "pharmaceuticals" industry.

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Jazz Pharmaceuticals had 20 more articles in the media than Axsome Therapeutics. MarketBeat recorded 35 mentions for Jazz Pharmaceuticals and 15 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.59 beat Jazz Pharmaceuticals' score of 0.53 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	10 Very Positive mention(s)	7 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.15	-$183.17M	-$3.73	N/A
Jazz Pharmaceuticals	$4.60B	3.62	-$356.15M	$14.50	17.69

Axsome Therapeutics has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Axsome Therapeutics' net margin of -26.59%. Jazz Pharmaceuticals' return on equity of 33.97% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

Axsome Therapeutics presently has a consensus price target of $265.55, indicating a potential upside of 24.82%. Jazz Pharmaceuticals has a consensus price target of $272.74, indicating a potential upside of 6.31%. Given Axsome Therapeutics' higher possible upside, equities analysts clearly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.91
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Jazz Pharmaceuticals beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Axsome Therapeutics (NASDAQ:AXSM) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

In the previous week, Axsome Therapeutics had 3 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 15 mentions for Axsome Therapeutics and 12 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 1.36 beat Axsome Therapeutics' score of 0.59 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Axsome Therapeutics presently has a consensus price target of $265.55, suggesting a potential upside of 24.82%. Teva Pharmaceutical Industries has a consensus price target of $42.00, suggesting a potential upside of 18.98%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Axsome Therapeutics is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.91
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Teva Pharmaceutical Industries has a net margin of 4.08% compared to Axsome Therapeutics' net margin of -26.59%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

Axsome Therapeutics has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Teva Pharmaceutical Industries has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.15	-$183.17M	-$3.73	N/A
Teva Pharmaceutical Industries	$17.26B	2.38	$1.41B	$0.60	58.83

Summary

Teva Pharmaceutical Industries beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

BeOne Medicines has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.15	$286.93M	$5.68	61.32
Axsome Therapeutics	$638.50M	17.15	-$183.17M	-$3.73	N/A

In the previous week, BeOne Medicines had 17 more articles in the media than Axsome Therapeutics. MarketBeat recorded 32 mentions for BeOne Medicines and 15 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.59 beat BeOne Medicines' score of 0.48 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	9 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Axsome Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

BeOne Medicines presently has a consensus target price of $400.00, suggesting a potential upside of 14.85%. Axsome Therapeutics has a consensus target price of $265.55, suggesting a potential upside of 24.82%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.88
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.91

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BeOne Medicines has a net margin of 10.70% compared to Axsome Therapeutics' net margin of -26.59%. BeOne Medicines' return on equity of 14.23% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Summary

BeOne Medicines and Axsome Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Axsome Therapeutics compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

Royalty Pharma has a net margin of 32.14% compared to Axsome Therapeutics' net margin of -26.59%. Royalty Pharma's return on equity of 30.01% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Royalty Pharma has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

Royalty Pharma has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	13.75	$770.95M	$1.45	39.15
Axsome Therapeutics	$638.50M	17.15	-$183.17M	-$3.73	N/A

In the previous week, Royalty Pharma had 6 more articles in the media than Axsome Therapeutics. MarketBeat recorded 21 mentions for Royalty Pharma and 15 mentions for Axsome Therapeutics. Royalty Pharma's average media sentiment score of 0.96 beat Axsome Therapeutics' score of 0.59 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	8 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Royalty Pharma currently has a consensus target price of $60.86, indicating a potential upside of 7.20%. Axsome Therapeutics has a consensus target price of $265.55, indicating a potential upside of 24.82%. Given Axsome Therapeutics' higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

Royalty Pharma beats Axsome Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to Zoetis?

Axsome Therapeutics (NASDAQ:AXSM) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

In the previous week, Zoetis had 29 more articles in the media than Axsome Therapeutics. MarketBeat recorded 44 mentions for Zoetis and 15 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.59 beat Zoetis' score of 0.58 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Zoetis	16 Very Positive mention(s)	4 Positive mention(s)	13 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Positive

Axsome Therapeutics presently has a consensus price target of $265.55, suggesting a potential upside of 24.82%. Zoetis has a consensus price target of $115.50, suggesting a potential upside of 59.25%. Given Zoetis' higher possible upside, analysts clearly believe Zoetis is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.91
Zoetis	1 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.35

Axsome Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Zoetis has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.15	-$183.17M	-$3.73	N/A
Zoetis	$9.47B	3.21	$2.67B	$6.07	11.95

Zoetis has a net margin of 27.49% compared to Axsome Therapeutics' net margin of -26.59%. Zoetis' return on equity of 74.89% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Zoetis	27.49%	74.89%	18.59%

Summary

Zoetis beats Axsome Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Axsome Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AXSM vs. The Competition

Export

Metric	Axsome Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.95B	$11.85B	$7.00B	$12.99B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-57.03	790.97	270.61	25.05
Price / Sales	17.15	970.27	657.91	107.93
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	121.57	10.38	11.26	6.43
Net Income	-$183.17M	$2.78B	$3.45B	$348.10M
7 Day Performance	0.81%	2.79%	3.41%	2.66%
1 Month Performance	-9.01%	-0.62%	-0.71%	-0.85%
1 Year Performance	103.00%	192.58%	77.43%	23.96%

Axsome Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AXSM Axsome Therapeutics	3.6668 of 5 stars	$212.74 flat	$265.55 +24.8%	+103.0%	$10.95B	$638.50M	N/A	380	Insider Trade
JAZZ Jazz Pharmaceuticals	3.2082 of 5 stars	$251.58 -0.5%	$259.06 +3.0%	+130.5%	$15.88B	$4.44B	N/A	2,890	Trending News Earnings Report High Trading Volume
TEVA Teva Pharmaceutical Industries	4.2337 of 5 stars	$34.39 -1.8%	$42.00 +22.1%	+116.0%	$40.25B	$17.26B	57.32	33,950
ONC BeOne Medicines	4.0953 of 5 stars	$313.77 -0.7%	$394.00 +25.6%	+20.9%	$34.67B	$5.34B	70.19	12,000	Trending News Earnings Report
RPRX Royalty Pharma	4.5695 of 5 stars	$57.17 -2.2%	$56.57 -1.0%	+51.1%	$33.65B	$2.38B	38.89	80	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AXSM) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Axsome Therapeutics (AXSM) Competitors

AXSM vs. JAZZ, TEVA, ONC, RPRX, and ZTS

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Summary

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Summary

How does Axsome Therapeutics compare to BeOne Medicines?

Summary

How does Axsome Therapeutics compare to Royalty Pharma?

Summary

How does Axsome Therapeutics compare to Zoetis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM vs. The Competition

Axsome Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Axsome Therapeutics (AXSM) Competitors

AXSM vs. JAZZ, TEVA, ONC, RPRX, and ZTS

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Does the media favor AXSM or JAZZ?

Which has preferable valuation and earnings, AXSM or JAZZ?

Which has more risk & volatility, AXSM or JAZZ?

Is AXSM or JAZZ more profitable?

Do analysts rate AXSM or JAZZ?

Do insiders and institutionals believe in AXSM or JAZZ?

Summary

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Does the media favor AXSM or TEVA?

Do institutionals and insiders hold more shares of AXSM or TEVA?

Do analysts rate AXSM or TEVA?

Is AXSM or TEVA more profitable?

Which has more risk and volatility, AXSM or TEVA?

Which has stronger earnings and valuation, AXSM or TEVA?

Summary

How does Axsome Therapeutics compare to BeOne Medicines?

Which has preferable valuation & earnings, ONC or AXSM?

Does the media prefer ONC or AXSM?

Which has more risk and volatility, ONC or AXSM?

Do analysts prefer ONC or AXSM?

Do institutionals & insiders have more ownership in ONC or AXSM?

Is ONC or AXSM more profitable?

Summary

How does Axsome Therapeutics compare to Royalty Pharma?

Is RPRX or AXSM more profitable?

Do insiders and institutionals believe in RPRX or AXSM?

Which has more volatility and risk, RPRX or AXSM?

Which has stronger earnings & valuation, RPRX or AXSM?

Does the media refer more to RPRX or AXSM?

Do analysts recommend RPRX or AXSM?

Summary

How does Axsome Therapeutics compare to Zoetis?

Does the media favor AXSM or ZTS?

Do analysts recommend AXSM or ZTS?

Which has more risk & volatility, AXSM or ZTS?

Do institutionals & insiders have more ownership in AXSM or ZTS?

Which has preferable earnings and valuation, AXSM or ZTS?

Is AXSM or ZTS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM vs. The Competition

Axsome Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools